Greg Frank is Director, Global Public Policy with Merck, where he leads Merck’s global antimicrobial resistance (AMR) and therapeutic pandemic preparedness, and neuroscience policy. Previously Dr. Frank served as Senior Director, Infectious Disease Policy at the Biotechnology Innovation Organization (BIO), where he led several infectious diseases policy issues, including AMR and vaccine regulatory & reimbursement policy. Prior to BIO, Dr. Frank led science and diagnostics policy at the Infectious Diseases Society of America (IDSA). Dr. Frank is a member of the National Academies of Science, Engineering, and Medicine Forum on Microbial Threats, the Leadership Council of the National Institute of Antimicrobial Resistant Research and Education (NIAMREE), the expert advisory committee for the Partnership to Fight Infectious Diseases and is serves on the Sepsis Alliance Innovation Collaborative. He is a Board member on the AMR Industry Alliance. Dr. Frank received his doctorate in viral immunology at the University of Pittsburgh and pursued his postdoctoral training at the Laboratory of Viral Diseases at the National Institute of Allergy & Infectious Diseases.